synthetic peptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-07-13. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
=== Sperm storage and egg cases === The female chain catshark is able to store sperm and lay eggs several days after initial copulation. The shark has been known to store sperm up to 843 days although, there are some circumstances of poor egg development in eggs laid later. It is suggested that this could be due to a number of factors including, senescence, low sperm viability, or water quality factors. Egg cases found in the oviduct are soft, pale yellow and translucent. They also feature two coiled tendrils, a key adaptation which allows snagging on rocks or man made structures, providing grounding and safety. When deposited, they become hardened and become dark amber with white bands.
An al Jazeera cameraman, Salah Hassan, reported various abuses in the Abu Ghraib prison complex, such as being forced to strip naked, standing up for 11 hours and being kicked when he collapsed, being forced to wear a vomit-covered jumpsuit, and many other abuses. He later also witnessed a 12- or 13-year-old girl who was stripped naked and beaten. Her brother was held in another cell and heard her screams.
==== Allosteric regulator ==== Acetyl-CoA serves as an allosteric regulator of pyruvate dehydrogenase kinase (PDK). It regulates through the ratio of acetyl-CoA versus CoA. Increased concentration of acetyl-CoA activates PDK. Acetyl-CoA is also an allosteric activator of pyruvate carboxylase.
Opposing Force received mainly positive reviews, holding a score of 85.45% on the review aggregator site GameRankings. In the United States, the game sold 108,008 copies by the end of 1999. Although figures for sales on Steam have not been released, Opposing Force eventually sold over 1.1 million copies at retail. Computer and Video Games reviewer Kim Randell noted that "Gearbox has obviously gone to great pains to provide a similar experience to the original". Praise was also given to the multiplayer; Randell stated that the new additions for multiplayer made it the area of Opposing Force that "really shines". Randell closed the review by concluding that Opposing Force is "an awesome achievement". Erik Wolpaw, writing for GameSpot, noted that as most expansion packs were mediocre, "it's appropriate that Gearbox Software's Opposing Force, the official expansion for the genre-redefining Half-Life, in turn sets a new standard of quality for future action-game mission packs". Wolpaw praised the design of the single-player campaign, commenting that "you can sense the designers' enthusiasm as one memorable scene unfolds after another, and it compels you to keep playing". Although criticizing some elements of the artificial intelligence and describing some of the new models as "merely window dressing", the review concluded that Opposing Force was an "impassioned application of creative design".
Sources: en.wikipedia.org
At its most fundamental level, inheritance in organisms occurs by passing discrete heritable units, called genes, from parents to offspring. This property was first observed by Gregor Mendel, who studied the segregation of heritable traits in pea plants, showing for example that flowers on a single plant were either purple or white—but never an intermediate between the two colors. The discrete versions of the same gene controlling the inherited appearance (phenotypes) are called alleles. In the case of the pea, which is a diploid species, each individual plant has two copies of each gene, one copy inherited from each parent. Many species, including humans, have this pattern of inheritance. Diploid organisms with two copies of the same allele of a given gene are called homozygous at that gene locus, while organisms with two different alleles of a given gene are called heterozygous. The set of alleles for a given organism is called its genotype, while the observable traits of the organism are called its phenotype. When organisms are heterozygous at a gene, often one allele is called dominant as its qualities dominate the phenotype of the organism, while the other allele is called recessive as its qualities recede and are not observed. Some alleles do not have complete dominance and instead have incomplete dominance by expressing an intermediate phenotype, or codominance by expressing both alleles at once. When a pair of organisms reproduce sexually, their offspring randomly inherit one of the two alleles from each parent.
That month, Amnesty International published their report, finding that Gaddafi's forces were responsible for numerous war crimes but added that a number of allegations of human rights abuses lacked credible evidence. The report added that "much Western media coverage has from the outset presented a very one-sided view of the logic of events, portraying the protest movement as entirely peaceful and repeatedly suggesting that the regime's security forces were unaccountably massacring unarmed demonstrators". In July, over 30 governments recognized the NTC as the legitimate government of Libya; Gaddafi called on his supporters to "Trample on those recognitions, trample on them under your feet ... They are worthless". In August, the Arab League recognized the NTC as "the legitimate representative of the Libyan state". Aided by NATO air cover, the rebel militia pushed westward, defeating loyalist armies and securing control of the centre of the country. Gaining the support of Amazigh (Berber) communities of the Nafusa Mountains, who had long been persecuted as non-Arabic speakers under Gaddafi, the NTC armies surrounded Gaddafi loyalists in several key areas of western Libya. In August, the rebels seized Zliten and Tripoli, ending the last vestiges of Gaddafist power. It is probable that without the NATO air strikes supporting the rebels, they would not have been able to advance west and Gaddafi's forces would have ultimately retaken control of eastern Libya.
Similarly, modifications to the tRNA-linked bases that differ from the host system may reduce the translation of proteins quantitatively and qualitatively. For example, translating a foreign gene in another host system that did not contain the required tRNA resulted in early termination at the codon where the tRNA was missing. Collectively, with heterologous expression, when the host translation systems are different from the native system that the genes are being introduced from, coding errors, frameshifts, or premature or improper sequence termination are frequent. Consequently, this leads to a lower yield of functional proteins or unintended overexpression of the protein. These errors are especially prominent with the significant and unnatural increase in demand for host system biological machinery. Often, this causes the reallocation of cellular resources from normal processes to the production of the heterologous protein. Specifically, this strains tRNA and amino acid supply, quality control systems and secretion systems, as well as NADPH required for anabolic processes. Moreover, unnatural heterologous protein buildup also leads to adverse host effects. Overall the implications are not only evident in low product yields but also host stress responses and decreased host viability. There are many areas of active research addressing these limitations of utilizing heterologous expression, especially in a commercial setting.
Sources: en.wikipedia.org
== Causes == Soft tissue sarcomas have been linked within families, so it is hypothesized that neurofibrosarcoma may be genetic, although researchers still do not know the exact cause of the disease. Evidence supporting this hypothesis includes loss of heterozygosity on the 17p chromosome. The p53 (a tumor suppressor gene in the normal population) genome on 17p in neurofibrosarcoma patients is mutated, increasing the probability of cancer. The normal p53 gene will regulate cell growth and inhibit any uncontrollable cell growth in the healthy population; since p53 is inactivated in neurofibrosarcoma patients, they are much more susceptible to developing tumors.
=== Deficiency === In 2000, The American Journal of Human Genetics reported two female siblings, aged 4 and 6 years, with intellectual disability and severe creatine deficiency in the brain. Arginine:glycine amidinotransferase (AGAT) catalyzes the first step of creatine synthesis, resulting in the formation of guanidinoacetate, which is a substrate for creatine formation. In two female siblings with intellectual disability who had brain creatine deficiency that was reversible by means of oral creatine supplementation and had low urinary guanidinoacetate concentrations, Arginine:glycine amidinotransferase deficiency was identified as a new genetic defect in creatine metabolism. It is one of three cerebral creatine deficiencies. Patients with brain creatine deficiency present nonspecific neurologic symptoms, including intellectual disability, language disorders, epilepsy, autistic-like behavior, neurologic deterioration, and movement disorders. A deficiency in AGAT results in a creatine deficiency in the body. The treatment for this is creatine supplements since the body cannot make the creatine on its own. The positive results of creatine treatment (in AGAT deficiencies) and the observation that fetal and early postnatal development are normal in these patients support the hypothesis that earlier diagnosis and treatment can substantially improve the final prognosis of these diseases. Brain 1H-MRS examination is a reliable and minimally invasive technique to assess brain creatine disorders.
==== Eukaryotic algae ==== In nearly all species of eukaryotic algae (Chloromonas being one notable exception), upon induction of the CCM, ~95% of RuBisCO is densely packed into a single subcellular compartment: the pyrenoid. Carbon dioxide is concentrated in this compartment using a combination of CO2 pumps, bicarbonate pumps, and carbonic anhydrases. The pyrenoid is not a membrane-bound compartment but is found within the chloroplast, often surrounded by a starch sheath (which is not thought to serve a function in the CCM).
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.